Jeff Paley

[Jeff Paley @jeffpaleymd]

Hi Biotwitter! I am helping an exciting private biotech to raise money and am looking for angel investors. The company is 18 months away from an IND, has a proven management team and has 10x upside in 18-24 months. If anyone is interested , please DM me asap.

[Jeff Paley @jeffpaleymd]

@MattyKirsh I meant to write a "pure ARDS trial, which is now ongoing"

[Jeff Paley @jeffpaleymd]

@MattyKirsh As you can see from my many posts on $EDSA, I follow it closely. The problem is that at present, it appears to be ONLY a COVID-associated ARDS story. If it succeeds in an ongoing pure ARDS story, it is another 10-20X

[Jeff Paley @jeffpaleymd]

@Mulhollandrivee Neat!! How do you know her (or how do you know OF her)?

[Jeff Paley @jeffpaleymd]

$CLNN-(continued), it was still statistically significant and James Berry of MGH is no slouch. I think the upside here if approved is staggering.

[Jeff Paley @jeffpaleymd]

@adamfeuerstein @QueenBioInvest Hi ,Great one!! finally bought all of the stat options--love it!

[Jeff Paley @jeffpaleymd]

@QueenBioInvest @Sanctuary_Bio @adamfeuerstein well said and I agree--you are very eloquent and educated. Willl follow you! favorite idea?

[Jeff Paley @jeffpaleymd]

$IOVA Turnaround underway. Replimune sidelined; sarcoma data; now emdometrial ca data (though n=5)
Need to replace hyperbolic CEO, but otherwise this is going higher

[Jeff Paley @jeffpaleymd]

$edsa Looks like a great short now on the need for a financing. I still cant entirely explain why the company canceleld their Bloom Burton conference meeting at the last moment. Would NOT short though as one might get caught in an ongoing squeeze

[Jeff Paley @jeffpaleymd]

$edsa Sold my entire position in EDSA after a 1500% 2 month return (bought at $1.22 and sold all > $17)

Story is over---the ARDS story is likely entirely COVID ARDS and noone will care about the data due to be presented next week. Vitilgo drug interesting, but company needs $

[Jeff Paley @jeffpaleymd]

$CLNN Adam F (whom I greatly respect) bashed CLNN this morning. I disagree with him here as I am a big believer on the importance of Neurofilament light chains. While I agree the difference from placebo for CLNN's "drug" is not as strong as the Nfl data for Qalsody, (cont'd)

[Jeff Paley @jeffpaleymd]

$edsa--short squeeze on top of possible partnership, acquisition--or investors finally recognizing the value here

[Jeff Paley @jeffpaleymd]

$edsa--anyone who follows me and noted my March 23rd post would be up about 1000% in the last 2 months.....

[Jeff Paley @jeffpaleymd]

$edsa-was supposed to present at the Bloom Burton conference today but canceled. Could be an imminent financing , the CEO is ill (but then why couldn't someone else step in?), or there's another development thats imminent. Could be great news or bad(FDA issue ?)

[Jeff Paley @jeffpaleymd]

@adamfeuerstein Love it, but technically, since you as a journalist have pre-release access to key news, isnt that material info on LABU and LABD. for example?

[Jeff Paley @jeffpaleymd]

$EDSA--finally, there are many drugs available for vitiligo, but CXCL10, Edesa's EB06 antibody target, has highly compelling preclinical data as the key pathogenetic mechanism. I repeat and again caution that company desperately needs $ but this is a remarkably undervalued story

[Jeff Paley @jeffpaleymd]

$edsa--also dont know if anyone noticed, but a filing shows that Perceptive Biosciences bought EDSA--The fund manager is arguably the best in biotech land, except perhaps the Baker brothers---If Perceptive made the effort to buy a tiny stock like this, that is quite remarkable!

[Jeff Paley @jeffpaleymd]

$EDSA---I was called late yesterday by Schwab to see if they could use my shares to borrow for short sellers---Of course, I declined but this call suggests that this is a highly difficult stock to short---"no borrow"--stock could soar again if momentum carries it

[Jeff Paley @jeffpaleymd]

$EDSA-Mgmt also "postponed" a call on Thursday with a great friend of mine who is a top Street analyst. They are either very shady or a deal is in the works. Could be a dilutive financing or could be a great licensing deal. Who knows?